| human | Q5 |
| P6178 | Dimensions author ID | 01315444670.22 |
| P2798 | Loop ID | 461 |
| P496 | ORCID iD | 0000-0002-6052-9438 |
| P3829 | Publons author ID | 2528114 |
| P1053 | ResearcherID | F-8752-2014 |
| P1153 | Scopus author ID | 7006307857 |
| P10861 | Springer Nature person ID | 01315444670.22 |
| P184 | doctoral advisor | René Misslin | Q119499931 |
| P735 | given name | Guy | Q1159023 |
| Guy | Q1159023 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q77801199 | 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. |
| Q43926211 | 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Bi |
| Q72040779 | 5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone |
| Q40465103 | 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research |
| Q28297569 | 50 years of hurdles and hope in anxiolytic drug discovery |
| Q51102784 | A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. |
| Q50652493 | AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. |
| Q28302527 | AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters |
| Q51138101 | Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. |
| Q48313661 | Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD). |
| Q28259081 | Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models |
| Q73591326 | An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome |
| Q45024827 | Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression |
| Q46923731 | Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. |
| Q46718531 | Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. |
| Q24634257 | Antidepressants recruit new neurons to improve stress response regulation |
| Q24534256 | Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. |
| Q34243167 | Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice |
| Q48246023 | Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats |
| Q43719558 | Behavioral and neurochemical changes following predatory stress in mice. |
| Q51086731 | Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. |
| Q48374869 | Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels |
| Q48870955 | Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors |
| Q48399050 | Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys |
| Q41146482 | Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice |
| Q51452187 | Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists. |
| Q51103621 | Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. |
| Q47850682 | Benzodiazepine and serotonergic modulation of antipredator and conspecific defense |
| Q51079730 | Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. |
| Q44709359 | Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression |
| Q43535348 | CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents |
| Q46487734 | Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia |
| Q47726493 | Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone |
| Q34110269 | Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. |
| Q35601756 | Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. |
| Q45248663 | Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihyd |
| Q48142913 | Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling |
| Q37159953 | Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal |
| Q43736831 | Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. |
| Q51464353 | Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice. |
| Q51123694 | Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. |
| Q48443500 | Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats |
| Q41672209 | Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries |
| Q48153057 | Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders |
| Q33748908 | Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. |
| Q46547612 | Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs |
| Q46649293 | Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal |
| Q43802617 | Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents |
| Q42904542 | Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery |
| Q44790146 | Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters |
| Q45251047 | Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents |
| Q34203078 | Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. |
| Q51109796 | Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. |
| Q45059328 | Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. |
| Q48783302 | Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety |
| Q48200438 | Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats |
| Q71491008 | Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam |
| Q83384523 | Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders |
| Q44701031 | Impaired memory following predatory stress in mice is improved by fluoxetine |
| Q43278466 | Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress |
| Q33643154 | Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? |
| Q37941286 | Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? |
| Q52179007 | Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. |
| Q50582873 | Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD. |
| Q46719102 | Long-term impaired memory following predatory stress in mice. |
| Q34420641 | Measuring normal and pathological anxiety-like behaviour in mice: a review. |
| Q37705481 | Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet. |
| Q34264829 | Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. |
| Q46547623 | Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic |
| Q35579520 | Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders |
| Q36447243 | Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. |
| Q51436366 | New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. |
| Q45006435 | Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). |
| Q38204177 | Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis |
| Q48156142 | Orphanin FQ, a novel neuropeptide with anti-stress-like activity |
| Q48148737 | Pharmacological studies on synthetic flavonoids: comparison with diazepam |
| Q51010332 | Pharmacology, Biochemistry and Behavior: the 2015 transition. |
| Q44116563 | Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia? |
| Q52201315 | Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357. |
| Q41155015 | Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks |
| Q34926526 | Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. |
| Q43808932 | Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. |
| Q48533916 | Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice |
| Q37807747 | Risk assessment as an evolved threat detection and analysis process |
| Q52193324 | Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. |
| Q46259554 | SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents |
| Q34561031 | SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. |
| Q46437564 | SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit |
| Q42677488 | SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities |
| Q44864695 | SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats |
| Q34159647 | SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. [...] |
| Q43063049 | Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression |
| Q51172279 | Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice. |
| Q54049252 | Some critical determinants of the behaviour of rats in the elevated plus-maze. |
| Q34623015 | Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. |
| Q51455021 | Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity. |
| Q48485331 | The CRF₁ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis |
| Q44988100 | The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine |
| Q48012691 | The CRF₁ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine |
| Q44713602 | The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice |
| Q42629405 | The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety |
| Q30475523 | The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice |
| Q95414178 | The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition |
| Q38461352 | The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies |
| Q48862784 | m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice |
| Q119499931 | René Misslin | doctoral student | P185 |
Search more.